Table 2.
Available Studies Related to Use of Mesenchymal Stem Cell in MS
| Authors | Country | Mesenchymal Stem cell | Model | Findings |
|---|---|---|---|---|
| Bonab et al., 2012 | Iran | Autologous bone marrow derived mesenchymal stem cell (BM-MSC) | Human | MSC therapy can improve/stabilize the course of the disease in progressive MS in the first year after injection with no serious adverse effects(109) |
| Payne et al., 2012 | Australia | bone marrow derived mesenchymal stem cell (BM-MSC) | Mouse | MSCs as a cell therapeutic that may be used to treat MS patients(110) |
| Cobo et al., 2012 | Spain | allogenicmesenchymal stem cells (MSCs) | Mouse | Unmodified MSCs were not therapeutic when administer at the peak of disease(111) |
| Al Jumah et al., 2012 | Saudi Arabia | Mesenchymal stem cells (MSCs | Mouse | effectiveness of MSCs in modulating the immunopathogenic process and in providing neuroprotection in MS(112) |
| Fisher-Shoval et al., 2012 | Israel | human placental MSCs (PL-MSCs) | Mouse | PL-MSCs have a therapeutic effect in the EAE mice modelof MS(113) |
| Bai et al., 2012 | USA | Mesenchymal stem cells (MSCs) | Mouse | MSC-stimulated functional recovery in animal models of MS(114) |
| Payne et al., 2012 | Australia | human adipose-derived MSCs (Ad-MSCs) | Mouse | Ad-MSCs express anti-inflammatory cytokines may provide a rational approach to promote immunomodulation and tissue protection in MS(115) |
| Connick et al., 2012 | UK | Autologous mesenchymal stem cells | Human | The evidence of structural, functional, and physiological improvement after treatment in some visual endpoints is suggestive of neuroprotection in MS(116) |
| Zhang et al., 2012 | China | NT-3 gene-modified MSC | Rat | genetically modified MSCs could be a potential therapeutic avenue for improving the efficacy of stem cell treatment for neurodegenerative diseases such as MS(117) |
| Harris et al., 2012 | USA | bone marrow mesenchymal stem cell-derived neural progenitors (MSC-NPs) | Human | MSC-NPs may influence the rate of repair through effects on endogenous progenitors in the spinal cord in MS(118) |
| Odinak et al., 2011 | Russia | autologicmultipotentmesenchymal stem cells (MSC) | Human | safety of the elaborated protocol of treatment and the moderate clinical efficacy of treatment in MS patients or those with poor response to treatment(119) |
| Mohajeri et al., 2011 | Iran | bone marrow derived mesenchymal stem cells | Human | support the potential of bone marrow derived MSC for treatment of MS patients(120) |
| Grigoriadis et al., 2011 | Greece | Autologous bone marrow stromal cells (BMSCs) | Mouse | substantial relevance for clinical trials in MS, particularly regarding the possibility that transplanted BMSCs entering the inflamed central nervous system(121) |
| Cristofanilli et al., 2011 | USA | embryonic-derived oligodendrocyte progenitor cells (OPCs)- Mesenchymal stem cells (MSCs) | Mouse | combining the immunomodulatory and trophic properties of MSCs with the myelinating ability of OPCs might be a suitable strategy for promoting neurological regeneration in MS(122) |
| Karussis et al., 2010 | Israel | autologous mesenchymalstem cells (MSCs) | Human | Transplantation of MSCs in patients with MS is a clinically feasible and relatively safe procedure and induces immediate immunomodulatory effects(49) |
| Yamout et al., 2010 | Lebanon | autologous bone marrow derived mesenchymal stem cells (BM-MSCs) | Human | clinical but not radiological efficacy and evidence of safety with no serious adverse events in MS(50) |
| Darlington et al., 2010 | Canada | bone marrow-derived hMSCs | Human | importance of further preclinical work and immune-monitoring to define hMSC effects on disease-relevant immune responses under variable conditions in MS(123) |
| Rice et al., 2010 | UK | autologous bone marrow-derived mesenchymal stem cells (MSCs) | Human | therapeutic potential of autologous MSCs which primarily utilize MSCs from individuals without MS, and relevance to clinical studies extrapolating from these scientific findings(124) |
| Mallam et al., 2010 | UK | human MSCs (hMSC) | Human | implications for the development of new therapeutic interventions designed to mobilize endogenous cells to enhance repair in MS(125) |
| Barhum et al., 2010 | Israel | Bone marrow mesenchymal stem cells (MSCs) | Mouse | NTFCs-transplanted ICV delay disease symptoms of EAE mice, possibly via neuroprotection and immunomodulation, and may serve as a possible treatment to MS(126) |
| Constantin et al., 2009 | Italy | adipose-derived MSCs (ASCs) | Mouse | ASCs represent a valuable tool for stem cell-based therapy in chronic inflammatory diseases of the CNS such as MS(127) |
| Liang et al., 2009 | China | mesenchymal stem cells | Human | mesenchymal stem cells have a potent immunosuppressive effect in MS(128) |
| Bai et al., 2009 | USA | human bone marrow-derived MSCs (BM-hMSCs) | Mouse | BM-hMSCs represent a viable option for therapeutic approaches in MS(129) |
| Mohyeddin et al., 2007 | Iran | Autologous Mesenchymal stem cells (MSCs) | Human | emphasizes on the feasibility of autologous MSC for treatment of MS patients(130) |